Breaks Categories: News

FridayApr 07, 2017 2:26 pm

NetworkNewsBreaks – CytoDyn Inc. (CYDY) Schedules Investment Community Conference Call for April 18

Biotechnology company CytoDyn Inc. (OTCQB: CYDY) yesterday announced that its management team will be hosting an investment community conference call to provide an update on the company’s latest clinical trial and regulatory developments. The call is scheduled for Tuesday, April 18, 2017, at 4:00 p.m. ET. Interested participants and investors can access the conference call by dialing 877-407-2986 from the United States and Canada or 201-378-4916 from international locations. Additionally, a live audio webcast of the call will be made available under the Investor Relations section of www.CytoDyn.com. This webcast will be archived for 60 days for the convenience of…

Continue Reading

FridayApr 07, 2017 11:51 am

NetworkNewsBreaks – Luminar Media Group, Inc. (LRGR) Says University Heath Network will Test TherOZap™ against Zika, West Nile Viruses; Shares Higher

Luminar Media Group (OTC: LRGR) shares are up 7% after the company, in conjunction with The Jenex Corporation, this morning reported the completion of a working prototype for the patent-pending TherOZap™ device. Additionally, the University Health Network has entered an agreement to test Therozap™ against the Zika and West Nile viruses. “The availability of a working prototype brings us one step closer to releasing this product to market. Expanding the device's effectiveness to the Zika and West Nile virus will provide tremendous benefit for many regions of the world,” CEO and chairman of Luminar Chris Cook stated in the news…

Continue Reading

ThursdayApr 06, 2017 2:27 pm

NetworkNewsBreaks – Achillion (NASDAQ: ACHN) Initiates Patient Dosing in ACH-4471 Phase 2 Study to Treat PNH

Achillion Pharmaceuticals (NASDAQ: ACHN) this morning said it has initiated patient dosing in a phase 2 open-label study of ACH-4471 for patients with paroxysmal nocturnal hemoglobinuria (PNH). ACH-4471 is the company’s first orally-administered, small molecule factor D inhibitor. The study will assess the efficacy, safety, and pharmacokinetics of ACH-4471 in untreated patients with PNH. “We are pleased to have begun this trial in PNH patients to evaluate ACH-4471, the first orally-administered factor D inhibitor to have demonstrated complement alternative pathway (AP) inhibition in humans, which represents a potentially novel and unique mechanistic approach to treating this life-threatening disease,” president and…

Continue Reading

ThursdayApr 06, 2017 12:26 pm

NetworkNewsBreaks – Player’s Network, Inc. (PNTV) CEO Releases Letter to Shareholders

Diversified holding company Player's Network, Inc. (OTCQB: PNTV) today released a shareholder letter from CEO Mark Bradley discussing several of the company’s recent achievements, as well as its corporate outlook for the remainder of 2017. Among PNTV’s first quarter highlights, the company completed an uplisting to the OTCQB® Venture Market and paid down the majority of its outstanding debt. Through its Green Leaf Farms Holdings ("GLFH") subsidiary, of which PNTV owns an 86 percent stake, the company also received a Certificate of Occupancy from the City of North Las Vegas for the first phase of a planned 27,000-square-foot facility that…

Continue Reading

ThursdayApr 06, 2017 11:03 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Broadens its Horizon with Pipeline of Cannabis-Based Therapies

Since its inception in 2005, India Globalization Capital (NYSE: IGC) has transitioned from a mining company to a developer of cannabis-based therapies. The company is unique in that it uses cannabis-based extracts in combination with other medications to reduce side effects and increase bioavailability and absorption. “The company now has a pipeline of patent pending cannabinoid-based drugs targeting large market maladies, which includes therapeutics for neuropathic pain, human and animal seizures, refractory epilepsy and eating disorders. Several of these therapeutic drugs are scheduled for pre-clinical trials this year. The company is transitioning fast from building research teams and developing a…

Continue Reading

WednesdayApr 05, 2017 12:16 pm

NetworkNewsBreaks – Plug Power, Inc. (NASDAQ: PLUG) Inks Deal with Amazon (NASDAQ: AMZN); Shares Surge

Shares of Plug Power (NASDAQ:PLUG) jumped more than 60% early morning after the energy solutions provider announced its agreement with Amazon (NASDAQ: AMZN) in which the e-commerce company will utilize Plug Power fuel cells and hydrogen technology at select fulfillment center locations.  Amazon will begin powering its industrial equipment using the GenKey technology to achieve faster charging times and reduced costs while supporting energy-efficiency in fulfillment operations. Revenues associated with the commercial agreements are expected to be around $70 million in 2017. “This agreement is a tremendous opportunity for Plug Power to further innovate and grow while helping to support…

Continue Reading

WednesdayApr 05, 2017 11:14 am

NetworkNewsBreaks – ChineseInvestors.com, Inc. (CIIX) Attending ‘Invest 2017’ Exhibition

Market analysis company ChineseInvestors.com, Inc. (OTCQB: CIIX) this morning announced plans to attend the ‘Invest 2017’ exhibition, which is set to take place on April 7-8 in Stuttgart, Germany. Noted as the leading trade fair and congress for finance and investment in Germany, Invest 2017 is expected to provide CIIX with an opportunity to introduce its media and nutritional hemp companies to a crowd of German investors. “I am delighted that CIIX is invited to attend Invest 2017 as an exhibitor,” Warren Wang, founder and CEO of CIIX, stated in this morning’s news release. “This exhibition provides CIIX a valuable…

Continue Reading

WednesdayApr 05, 2017 10:38 am

NetworkNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary Adds Apple Pay Support in Russia

Mobile payment technology company Net Element, Inc. (NASDAQ: NETE), through its PayOnline subsidiary, this morning announced the launch of Apple Pay support for its Russian markets. “As the shift to mobile payments continues, PayOnline delivers the necessary support and tools merchants need to make payments a seamless part of online and mobile purchases,” Marat Abasaliev, head of online solutions for PayOnline, stated in the news release. “By delivering support to merchants that use Apple Pay, PayOnline demonstrates its ability to meet the growing demand for secure, convenient and quick transactions.” According to data from Apple, the global number of Apple…

Continue Reading

WednesdayApr 05, 2017 10:11 am

NetworkNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Announces Sale of Brilliant Hallmark Stake

India Globalization Capital, Inc. (NYSE MKT: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced the sale of its investment interest in Brilliant Hallmark for a consideration of four million shares of IGC. The shares, which were previously issued to Brilliant Hallmark on August 4, 2016, will be returned and retired, while the Brilliant Hallmark investment will be removed from the company's balance sheet with an associated reduction of roughly $1.88 million. Per this morning’s update, IGC does not expect to record a gain or loss from this transaction. “This strategic move is…

Continue Reading

TuesdayApr 04, 2017 3:50 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (IMLFF) Takes Aim at Rare Skin Diseases with INM-750

Epidermolysis bullosa (EBS) is a group of rare inherited skin diseases that unfortunately have no currently approved or known cure or treatment. InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has developed INM-750 as the first therapy to specifically treat EBS. “Earlier this month, InMed filed an international Patent Cooperation Treaty application for intellectual and commercial protection of INM-750 and a cannabinoid-based therapy for EBS. This marks a significant milestone for the company, serving as validation for its efforts to develop new therapies based on cannabinoids and its unique approach to drug development. The company is using a proprietary bioinformatics assessment tool to…

Continue Reading